1-6 of 6
Qin Qin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How
Journal: Blood
Blood (2022) 140 (Supplement 1): 583–585.
https://doi.org/10.1182/blood-2022-157949
Published: 2022
Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
https://doi.org/10.1182/blood-2020-139705
Published: 2020
Journal Articles

Quantification of Whole-Brain Oxygenation Extraction Fraction Among People with Sickle Cell Anemia without Stroke History

Wenbo Li, PhD, Xiang Xu, PhD, Peiying Liu, PhD, Emily Jacobs, B.S., John J. Strouse, MD PhD, James F. Casella, MD, Hanzhang Lu, PhD, Peter van Zijl, PhD, Qin Qin, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3524.
https://doi.org/10.1182/blood.V130.Suppl_1.3524.3524
Published: 2017
Journal Articles

Simultaneous Measurement of Cerebral Blood Flow and Arterial Transit Time for Sickle Cell Disease

Qin Qin, PhD, Wenbo Li, PhD, Dexiang Liu, MD, John J Strouse, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1298.
https://doi.org/10.1182/blood.V128.22.1298.1298
Published: 2016
Journal Articles

Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.

Guillermo Garcia-Manero, MD, Raoul Tibes, MD, Yi-Lin Chiu, PhD, Hao Xiong, PhD, Qin Qin, Peter Ansell, PhD, Daniel H. Albert, PhD, BSc, Chris Tse, PhD, Brian Oliver, Karim Sajwani, MS, Mark D. McKee, MD, Justin L. Ricker, MD, PhD, H. Jean Khoury, MD
Journal: Blood
Blood (2012) 120 (21): 2617.
https://doi.org/10.1182/blood.V120.21.2617.2617
Published: 2012
Journal Articles

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Wendy Stock, MD, Karen WL Yee, MD, Eunice S. Wang, MD, Sari Enschede, MD, Joyce Steinberg, MD, Rod Humerickhouse, MD, PhD, Qin Qin, PhD, Jiang Qian, PhD, Yi-Lin Chiu, PhD, Neeraj Gupta, PhD, Rajendra Pradhan, PhD
Journal: Blood
Blood (2008) 112 (11): 4008.
https://doi.org/10.1182/blood.V112.11.4008.4008
Published: 2008